Latest news and press releases about Forte Biosciences, Inc. (FBRX): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Forte Biosciences, Inc. is a U.S.-based biopharmaceutical company currently in its clinical development phase. The firm's key initiative involves advancing the FB-102 program, which is designed to tackle a variety of autoimmune conditions, notably vitiligo and alopecia areata. Their main offices are situated in Dallas, Texas.
Price
| Price | $76.99 |
| Market Cap | $1.6B |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 9.96 |
| EV / EBITDA | -17.71 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -94.82% |
| Return on Invested Capital | -48.53% |
| Return on Assets | -42.74% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: ACTU · ALEC · APLT · CRBP · CRDF · ELTX · FATE
Explore sector: Healthcare · Biotechnology
More sections of FBRX: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks